Literature DB >> 33665168

The Prognostic Value of Retroperitoneal Lymphadenectomy in Apparent Stage IA Endometrial Endometrioid Cancer.

Zhao Liu1,2, Jinghe Lang1, Ming Wu1, Lei Li1.   

Abstract

STUDY
DESIGN: Retrospective cohort study.
INTRODUCTION: Debates remain regarding the role of lymphadenectomy in patients with apparent stage IA endometrial cancer, especially subtypes with a favorable prognosis. This study aimed to explore the prognostic value of staging surgeries in apparent stage IA endometrial endometrioid cancer patients in a retrospective cohort study.
METHODS: Cases from June 1, 2010 to June 1, 2017 were reviewed in patients with pathologically confirmed endometrial endometrioid carcinoma limited to <1/2 of the myometrium, without extrauterine metastasis on preoperative evaluation and during surgical inspection. Survival outcomes were compared between patients with and without lymphadenectomy and between patients with and without metastasis to lymph nodes.
RESULTS: In total, 1,312 eligible patients were included, among which 836 underwent staging surgeries and 476 underwent simple hysterectomy. Twenty-eight patients were found with metastasis to retroperitoneal lymph nodes. After a median follow-up of 57.4 months, lost to follow-up, recurrence, death, and cancer-specific death occurred in 28, 39, 24, and 16 patients, respectively. In a univariate analysis, lymphadenectomy of the pelvis with or without para-aortic lymph nodes had no significant impact on disease-free survival, overall survival or cancer-specific overall survival (p values >0.05). However, after adjusting for important baseline risk factors [menopausal status, tumor differentiation, maximum diameter and location, lymph-vascular space invasion (LVSI) status, and postoperative adjuvant therapy), lymphadenectomy resulted in significantly improved survival outcomes (p values <0.05). Menopause (odds ratio [OR] 4.7, 95% confidence interval [CI] 1.3-16.4, p=0.015), tumor diameter larger than 2 cm (OR 4.6, 95% CI 1.3-16.0, p=0.016), grade 3 tumors (OR 3.0, 95% CI 1.0-8.5, p=0.042), positive LVSI (OR 8.7, 95% CI 3.7-20.4, p<0.001) and lower uterine segment involvement (OR 3.1, 95% CI 1.4-7.2, p=0.007) had more extrauterine metastases.
CONCLUSION: In cases of apparent stage IA endometrioid endometrial carcinoma, staging surgeries should be considered in patients with larger, higher grade tumors, positive LVSI, or lower uterine segment involvement.
Copyright © 2021 Liu, Lang, Wu and Li.

Entities:  

Keywords:  disease-free survival; endometrial carcinoma; endometrioid subtype; lymph node metastasis; overall survival

Year:  2021        PMID: 33665168      PMCID: PMC7921700          DOI: 10.3389/fonc.2020.618499

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  33 in total

1.  Lymphadenectomy for endometrial cancer: the controversy.

Authors:  Leigh G Seamon; Jeffrey M Fowler; David E Cohn
Journal:  Gynecol Oncol       Date:  2010-01-29       Impact factor: 5.482

Review 2.  Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis.

Authors:  Jeffrey A How; Patrick O'Farrell; Zainab Amajoud; Susie Lau; Shannon Salvador; Emily How; Walter H Gotlieb
Journal:  Minerva Ginecol       Date:  2017-11-28

Review 3.  Meta-analysis of laparoscopy sentinel lymph node mapping in endometrial cancer.

Authors:  Lijun Wang; Fang Liu
Journal:  Arch Gynecol Obstet       Date:  2018-07-14       Impact factor: 2.344

Review 4.  The Role of Lymphadenectomy Versus Sentinel Lymph Node Biopsy in Early-stage Endometrial Cancer: A Review of the Literature.

Authors:  Roi Tschernichovsky; Elisabeth J Diver; John O Schorge; Annekathryn Goodman
Journal:  Am J Clin Oncol       Date:  2016-10       Impact factor: 2.339

Review 5.  Current recommendations and recent progress in endometrial cancer.

Authors:  Rebecca A Brooks; Gini F Fleming; Ricardo R Lastra; Nita K Lee; John W Moroney; Christina H Son; Ken Tatebe; Jennifer L Veneris
Journal:  CA Cancer J Clin       Date:  2019-05-10       Impact factor: 508.702

6.  Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer.

Authors:  S Kumar; A Mariani; J N Bakkum-Gamez; A L Weaver; M E McGree; G L Keeney; W A Cliby; K C Podratz; S C Dowdy
Journal:  Gynecol Oncol       Date:  2013-06-05       Impact factor: 5.482

Review 7.  Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging - a systematic review.

Authors:  Anabela Rocha; Ana Maria Domínguez; Fabrice Lécuru; Nicolas Bourdel
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2016-09-30       Impact factor: 2.435

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

9.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

Authors:  H Kitchener; A M C Swart; Q Qian; C Amos; M K B Parmar
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

10.  Contemporary clinical management of endometrial cancer.

Authors:  Helen E Dinkelspiel; Jason D Wright; Sharyn N Lewin; Thomas J Herzog
Journal:  Obstet Gynecol Int       Date:  2013-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.